ArticleFrontiers in oncology2026

Completion of ≥6 cycles of adjuvant temozolomide is the strongest modifiable prognostic factor in glioblastoma: a 17-year real-world cohort of 319 glioma patients from a single Chinese center.

Pei Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.